AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36962912 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse experiences in LQoL group
Number of subjects: 3998
Study 36962912 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual problems in LQoL group
Number of subjects: 3998
Study 36962912 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of LQoL group
Number of subjects: 3998
Study 36962953 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline seroprevalence of IgG antibodies to SARS-CoV-2
Number of subjects: 525
Study 36962953 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroconversion rates
Number of subjects: 525
Study 36962953 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in IgG concentration
Number of subjects: 525
Study 36962953 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom reporting
Number of subjects: 525
Study 36962953 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 525
Study 36962956 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Engagement (CE) strategy
Number of subjects: 19169
Study 36963004 — intervention group
Group type: EXPERIMENTAL
Intervention: ART/VL
Number of subjects: 46
Study 36963004 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP
Number of subjects: 46
Study 36963004 — intervention group
Group type: EXPERIMENTAL
Intervention: Semen Washing (SW)
Number of subjects: 46
Study 36963004 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Insemination (VI)
Number of subjects: 46
Study 36963004 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Safer Conception Program
Number of subjects: 46
Study 36963067 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum IUD (PPIUD) counselling and insertion intervention
Number of subjects: 0
Study 36963078 — intervention group
Group type: EXPERIMENTAL
Intervention: bCPAP device
Number of subjects: 14
Study 36963116 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning enabled MV-based real-time image guided radiation therapy
Number of subjects: 0
Study 36963127 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 49
Study 36963200 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and nab-paclitaxel every other week
Number of subjects: 0
Study 36963200 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5FU) and liposomal irinotecan (nal-IRI) every other week
Number of subjects: 0
Study 36963200 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 0
Study 36963203 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (PABLO system)
Number of subjects: 37
Study 36963203 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 37
Study 36963283 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19(+) cohort
Number of subjects: 196
Study 36963283 — intervention group
Group type: COMPARATOR
Intervention: COVID-19(-) cohort
Number of subjects: 196
Study 36963417 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (digital data informed treatment adjustments)
Number of subjects: 220
Study 36963417 — intervention group
Group type: COMPARATOR
Intervention: Control group (pharmacy refill rates informed treatment adjustments)
Number of subjects: 220
Study 36963502 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-1
Number of subjects: 1120
Study 36963502 — intervention group
Group type: EXPERIMENTAL
Intervention: sTFR
Number of subjects: 1120
Study 36963502 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF21
Number of subjects: 1120
Study 36963502 — intervention group
Group type: EXPERIMENTAL
Intervention: ferritin
Number of subjects: 1120
Study 36963502 — intervention group
Group type: EXPERIMENTAL
Intervention: collagen-X
Number of subjects: 1120
Study 36963502 — intervention group
Group type: EXPERIMENTAL
Intervention: CD14
Number of subjects: 1120
Study 36963502 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP4
Number of subjects: 1120
Study 36963502 — intervention group
Group type: EXPERIMENTAL
Intervention: AGP
Number of subjects: 1120
Study 36963502 — intervention group
Group type: EXPERIMENTAL
Intervention: thyroglobulin
Number of subjects: 1120
Study 36963502 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual biomarkers
Number of subjects: 1120
Study 36963504 — intervention group
Group type: EXPERIMENTAL
Intervention: % FFML at week 9
Number of subjects: 70
Study 36963504 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (WL) at week 9
Number of subjects: 70
Study 36963504 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight regain at 1 year
Number of subjects: 70
Study 36963515 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring Contacts with introductory phone call (CC+)
Number of subjects: 666
Study 36963515 — intervention group
Group type: COMPARATOR
Intervention: Caring Contacts without introductory phone call (CC)
Number of subjects: 666
Study 36963789 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologist-directed default palliative care referral orders (intervention arm)
Number of subjects: 250
Study 36963789 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control arm)
Number of subjects: 250
Study 36963790 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to reduce outdoor exposure to desert dust
Number of subjects: 0
Study 36963790 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to reduce both outdoor and indoor exposure to particulate matter during desert dust episodes
Number of subjects: 0
Study 36963790 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study 36963800 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application with education in its use plus conventional multidisciplinary rehabilitation programme (exercises and self-management education)
Number of subjects: 120
Study 36963800 — intervention group
Group type: COMPARATOR
Intervention: Conventional multidisciplinary rehabilitation programme (exercises and self-management education)
Number of subjects: 120
Study 36963815 — intervention group
Group type: EXPERIMENTAL
Intervention: Three additional 40 µg doses administered at monthly intervals (experimental arm)
Number of subjects: 120
Study 36963815 — intervention group
Group type: COMPARATOR
Intervention: Single 40 µg booster vaccination at month 6 (classical arm)
Number of subjects: 120
Study 36963820 — intervention group
Group type: EXPERIMENTAL
Intervention: North America
Number of subjects: 1118
Study 36963820 — intervention group
Group type: EXPERIMENTAL
Intervention: Europe
Number of subjects: 1118
Study 36963852 — intervention group
Group type: EXPERIMENTAL
Intervention: Premeal load of almonds (20 g) 30 minutes before major meals
Number of subjects: 66
Study 36963852 — intervention group
Group type: COMPARATOR
Intervention: Control arm (not specified)
Number of subjects: 66
Study 36963903 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorimetry-based nutritional support
Number of subjects: 0
Study 36963903 — intervention group
Group type: COMPARATOR
Intervention: Recommended Dietary Allowance (RDA) guidelines
Number of subjects: 0
Study 36964012 — intervention group
Group type: EXPERIMENTAL
Intervention: PENG block
Number of subjects: 112
Study 36964012 — intervention group
Group type: COMPARATOR
Intervention: No block (control)
Number of subjects: 112
Study 36964084 — intervention group
Group type: EXPERIMENTAL
Intervention: Presatovir 200 mg on day 1 and 100 mg daily on days 2 to 14
Number of subjects: 61
Study 36964084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 36964191 — intervention group
Group type: EXPERIMENTAL
Intervention: SBS3
Number of subjects: 223
Study 36964191 — intervention group
Group type: EXPERIMENTAL
Intervention: High HRD score
Number of subjects: 223
Study 36964191 — intervention group
Group type: EXPERIMENTAL
Intervention: Biallelic inactivation of HR gene
Number of subjects: 223
Study 36964415 — intervention group
Group type: EXPERIMENTAL
Intervention: CF + LI-featured catheter
Number of subjects: 120
Study 36964415 — intervention group
Group type: EXPERIMENTAL
Intervention: LI-featured catheter
Number of subjects: 120
Study 36964415 — intervention group
Group type: COMPARATOR
Intervention: Standard irrigated catheter
Number of subjects: 120
Study 36964422 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-TS (brief CBT for Treatment Seeking) delivered by phone
Number of subjects: 841
Study 36964422 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 841
Study 36964455 — intervention group
Group type: EXPERIMENTAL
Intervention: Data validation process through pilot audit in participating hospitals
Number of subjects: 330
Study 36964485 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-radiotherapy supervised exercise
Number of subjects: 144
Study 36964485 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-radiotherapy supervised exercise
Number of subjects: 144
Study 36964485 — intervention group
Group type: COMPARATOR
Intervention: Autonomous exercise
Number of subjects: 144
Study 36964485 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (pre-radiotherapy, post-radiotherapy, autonomous exercise)
Number of subjects: 144
Study 36964490 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve block
Number of subjects: 160
Study 36964490 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 160
Study 36964529 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic radiosurgery (SRS) with a dose of 15-24 Gy in 1 or 3 fractions
Number of subjects: 0
Study 36964529 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated stereotactic radiosurgery (fSRS) 35 Gy in five fractions
Number of subjects: 0
Study 36964529 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 0
Study 36964529 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated stereotactic radiosurgery (fSRS)
Number of subjects: 0
Study 36964541 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty (THA)
Number of subjects: 200
Study 36964582 — intervention group
Group type: EXPERIMENTAL
Intervention: ViBone VBM
Number of subjects: 0
Study 36964590 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative vasopressor infusions (PVI)
Number of subjects: 40000
Study 36964590 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative vasopressor usage
Number of subjects: 40000
Study 36964593 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral medicine intervention in physical therapy (BMIP) plus routine exercise-based cardiac rehabilitation (exCR)
Number of subjects: 170
Study 36964593 — intervention group
Group type: COMPARATOR
Intervention: Routine exercise-based cardiac rehabilitation (RC)
Number of subjects: 170
Study 36964608 — intervention group
Group type: EXPERIMENTAL
Intervention: webCHAT (single session online intervention)
Number of subjects: 150
Study 36964608 — intervention group
Group type: COMPARATOR
Intervention: usual driver education
Number of subjects: 150
Study 36964614 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound-guided fluid deresuscitation
Number of subjects: 1000
Study 36964614 — intervention group
Group type: COMPARATOR
Intervention: Control (deresuscitation at physician's discretion without LUS)
Number of subjects: 1000
Study 36964626 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial prophylactic exchange blood transfusion (SPEBT) approximately every 6-10 weeks until delivery
Number of subjects: 50
Study 36964626 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 36964872 — intervention group
Group type: EXPERIMENTAL
Intervention: CMAB008 3 mg/kg
Number of subjects: 384
Study 36964872 — intervention group
Group type: COMPARATOR
Intervention: Innovator infliximab 3 mg/kg
Number of subjects: 384
Study 36964872 — intervention group
Group type: EXPERIMENTAL
Intervention: CMAB008
Number of subjects: 384
Study 36964872 — intervention group
Group type: COMPARATOR
Intervention: Innovator infliximab
Number of subjects: 384
Study 36964872 — intervention group
Group type: EXPERIMENTAL
Intervention: CMAB008 and Innovator infliximab
Number of subjects: 384
Study 36964977 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance (IR) defined as an estimated glucose disposal rate (eGDR) ≤9.0 mg/kg/min
Number of subjects: 923
Study 36964977 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ≥10 years of T1D
Number of subjects: 923
Study 36964977 — intervention group
Group type: COMPARATOR
Intervention: Patients with <10 years of T1D
Number of subjects: 923
Study 36964977 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes duration
Number of subjects: 923
Study 36964977 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin dose
Number of subjects: 923
Study 36965105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Number of subjects: 0
Study 36965105 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 0
Study 36965173 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent COVID-19 plasma (CCP)
Number of subjects: 95
Study 36965196 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous suppression (CS) strategy
Number of subjects: 63
Study 36965196 — intervention group
Group type: COMPARATOR
Intervention: Search and destroy (SD) strategy
Number of subjects: 63
Study 36965232 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy (BBT)
Number of subjects: 52
Study 36965232 — intervention group
Group type: COMPARATOR
Intervention: Assisted Referral to Community Care (ARC)
Number of subjects: 52
Study 36965396 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent somatic symptoms
Number of subjects: 74
Study 36965396 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifying illness perception (IP)
Number of subjects: 74
Study 36965396 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual illness perception (IP)
Number of subjects: 74
Study 36965493 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult-led organized group settings for children, assessed through accelerometry and video observation.
Number of subjects: 1302
Study 36965493 — intervention group
Group type: EXPERIMENTAL
Intervention: Community data system for monitoring and feedback on physical activity.
Number of subjects: 1302
Study 36965550 — intervention group
Group type: EXPERIMENTAL
Intervention: High RNT MDD group
Number of subjects: 159
Study 36965550 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD (regardless of RNT intensity)
Number of subjects: 159
Study 36965550 — intervention group
Group type: EXPERIMENTAL
Intervention: RNT-nonspecific findings in MDD
Number of subjects: 159
Study 36965692 — intervention group
Group type: EXPERIMENTAL
Intervention: Menus with greater food weight
Number of subjects: 128
Study 36965692 — intervention group
Group type: EXPERIMENTAL
Intervention: Menus with higher energy density
Number of subjects: 128
Study 36965692 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily menus meeting dietary recommendations
Number of subjects: 128
Study 36965692 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with overweight and obesity
Number of subjects: 128
Study 36965692 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable intake
Number of subjects: 128
Study 36965692 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with lower satiety responsiveness or higher food responsiveness
Number of subjects: 128
Study 36965695 — intervention group
Group type: COMPARATOR
Intervention: Sterile gloves (powder-free polyvinyl chloride examination gloves)
Number of subjects: 163
Study 36965695 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean gloves (powder-free nitrile examination gloves)
Number of subjects: 163
Study 36965695 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined rates of infection (both groups)
Number of subjects: 163
Study 36965695 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with any infection (n=11)
Number of subjects: 163
Study 36965866 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonreportable cell-free DNA screening results
Number of subjects: 17851
Study 36965866 — intervention group
Group type: EXPERIMENTAL
Intervention: First nonreportable test
Number of subjects: 17851
Study 36965866 — intervention group
Group type: EXPERIMENTAL
Intervention: Second nonreportable test
Number of subjects: 17851
Study 36965866 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonreportable tests
Number of subjects: 17851
Study 36966023 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.15 mg/kg
Number of subjects: 50
Study 36966023 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 50
Study 36966023 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone group
Number of subjects: 50
Study 36966023 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 36966179 — intervention group
Group type: EXPERIMENTAL
Intervention: AI analysis arm (n=38)
Number of subjects: 109
Study 36966179 — intervention group
Group type: COMPARATOR
Intervention: No-AI analysis arm (n=38)
Number of subjects: 109
Study 36966310 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic synovectomy with deposition of corticosteroids
Number of subjects: 80
Study 36966310 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular corticosteroid injections (IACSI)
Number of subjects: 80
Study 36966349 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant melatonin 20 mg (4 tablets of 5 mg) at 10 pm for 5 years
Number of subjects: 100
Study 36966349 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up (control group)
Number of subjects: 100
Study 36966440 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 40
Study 36966799 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg once per day for 8 weeks plus standard tuberculosis therapy
Number of subjects: 137
Study 36966799 — intervention group
Group type: COMPARATOR
Intervention: Standard tuberculosis therapy alone (control group)
Number of subjects: 137
Study 36966799 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg once per day
Number of subjects: 137
Study 36966905 — intervention group
Group type: EXPERIMENTAL
Intervention: Third monovalent mRNA vaccines
Number of subjects: 81
Study 36966922 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-enabled electrocardiogram (AI-ECG)
Number of subjects: 1000
Study 36966953 — intervention group
Group type: COMPARATOR
Intervention: Standard GIST (n=24)
Number of subjects: 49
Study 36966953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive GIST (n=18)
Number of subjects: 49
Study 36967158 — intervention group
Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS)
Number of subjects: 30
Study 36967158 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides (FOS)
Number of subjects: 30
Study 36967158 — intervention group
Group type: COMPARATOR
Intervention: Acacia gum
Number of subjects: 30
Study 36967162 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma DHPPA concentration in NAFLD patients
Number of subjects: 1880
Study 36967162 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing tertiles of plasma DHPPA
Number of subjects: 1880
Study 36967162 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of plasma DHPPA
Number of subjects: 1880
Study 36967172 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary feeding
Number of subjects: 1791
Study 36967169 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal (74.2% energy)
Number of subjects: 20
Study 36967169 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (64.6% energy)
Number of subjects: 20
Study 36967169 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein meal (39.5% energy)
Number of subjects: 20
Study 36967189 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaghetti
Number of subjects: 30
Study 36967189 — intervention group
Group type: EXPERIMENTAL
Intervention: Penne
Number of subjects: 30
Study 36967189 — intervention group
Group type: COMPARATOR
Intervention: Couscous
Number of subjects: 30
Study 36967189 — intervention group
Group type: COMPARATOR
Intervention: Bread
Number of subjects: 30
Study 36967244 — intervention group
Group type: EXPERIMENTAL
Intervention: Teclistamab (1.5 mg/kg weekly)
Number of subjects: 0
Study 36967244 — intervention group
Group type: COMPARATOR
Intervention: Physician's Choice (PC) of therapy
Number of subjects: 0
Study 36967282 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine sedation
Number of subjects: 14
Study 36967282 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathe-squeeze task
Number of subjects: 14
Study 36967281 — intervention group
Group type: EXPERIMENTAL
Intervention: Pholcodine exposure within a year before anaesthesia
Number of subjects: 501
Study 36967281 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational exposure to quaternary ammonium compounds
Number of subjects: 501
Study 36967281 — intervention group
Group type: EXPERIMENTAL
Intervention: Pholcodine and quaternary ammonium sIgEs
Number of subjects: 501
Study 36967281 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients exposed to pholcodine 12 months before NMBA exposure
Number of subjects: 501
Study 36967448 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (DEX)
Number of subjects: 112
Study 36967470 — intervention group
Group type: EXPERIMENTAL
Intervention: Predominant nocturnal AF (n = 40)
Number of subjects: 278
Study 36967470 — intervention group
Group type: EXPERIMENTAL
Intervention: Predominant daytime AF (n = 43)
Number of subjects: 278
Study 36967470 — intervention group
Group type: COMPARATOR
Intervention: Mixed AF (n = 195)
Number of subjects: 278
Study 36967470 — intervention group
Group type: COMPARATOR
Intervention: Comparison of nocturnal vs. mixed AF
Number of subjects: 278
Study 36967470 — intervention group
Group type: COMPARATOR
Intervention: Comparison of daytime vs. mixed AF
Number of subjects: 278
Study 36967527 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of glucose-lowering drugs (specific drugs not mentioned)
Number of subjects: 1026
Study 36967527 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (in clinical pharmacokinetic trial, n=10)
Number of subjects: 1026
Study 36967681 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma risk alleles in CDHR3
Number of subjects: 1011
Study 36967681 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma risk alleles in GSDMA, GSDMB, IKZF3, ZPBP2, and ORMDL3
Number of subjects: 1011
Study 36967681 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma risk alleles
Number of subjects: 1011